EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Gene-based therapies for steatotic liver disease

Viktoriia Iakovleva, Ype P de Jong

Molecular Therapy · 2025-06 · 33 (6) · 2527-2547

DOI: 10.1016/j.ymthe.2025.04.024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025-06. Verfasst von Viktoriia Iakovleva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY 10021, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Fatty Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in nucleic acid delivery have positioned the liver as a key target for gene therapy, with adeno-associated virus vectors showing long-term effectiveness in treating hemophilia. Steatotic liver disease (SLD), the most common liver condition globally, primarily results from metabolic dysfunction-associated and alcohol-associated liver diseases. In some individuals, SLD progresses from simple steatosis to steatohepatitis, cirrhosis, and eventually hepatocellular carcinoma, driven by a complex interplay of genetic, metabolic, and environmental factors. Genetic variations in various lipid metabolism-related genes, such as patatin-like phospholipase domain-containing protein 3 (PNPLA3), 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13), and mitochondrial amidoxime-reducing component 1 (MTARC1), impact the progression of SLD and offer promising therapeutic targets. This review largely focuses on genes identified through clinical association studies, as they are more likely to be effective and safe for therapeutic intervention. While preclinical research continues to deepen our understanding of genetic factors, early-stage clinical trials involving gene-based SLD therapies, including transient antisense and small-molecule approaches, are helping prioritize therapeutic targets. Meanwhile, hepatocyte gene editing technologies are advancing rapidly, offering alternatives to transient methods. As such, gene-based therapies show significant potential for preventing the progression of SLD and enhancing long-term liver health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyFatty LiverHumansAnimalsGenetic VectorsLipid MetabolismDependovirus

Stichwörter der Autor:innen

AAVALDMASHMASLDNAFLD

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY 10021, USA.
  • Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY 10021, USA. Electronic address: ydj2001@med.cornell.edu.

Förderung

  • NHLBI NIH HHS
  • NIH

Zitieren

APA

Iakovleva, V., & de Jong, Y. P. (2025). Gene-based therapies for steatotic liver disease. Molecular Therapy, 33(6), 2527-2547. https://doi.org/10.1016/j.ymthe.2025.04.024

Vancouver

Iakovleva V, de Jong YP. Gene-based therapies for steatotic liver disease. Molecular Therapy. 2025;33(6):2527-2547. doi:10.1016/j.ymthe.2025.04.024

BibTeX
@article{Iakovleva2025,
  author = {Iakovleva, Viktoriia and de Jong, Ype P},
  title = {Gene-based therapies for steatotic liver disease},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {6},
  pages = {2527--2547},
  doi = {10.1016/j.ymthe.2025.04.024}
}
Kostenlos starten →